Latest Articles

Publication Date
All News Scientific
Is Vaginal Estrogen Safe After Endometrial Cancer? - Medscape

Is Vaginal Estrogen Safe After Endometrial Cancer? Medscape

Published: March 4, 2026, 5:49 p.m.
Read Full Article
Vaginal estrogen therapy is safe for young endometrial cancer survivors, study finds - News-Medical

Vaginal estrogen therapy is safe for young endometrial cancer survivors, study finds News-Medical

Published: March 4, 2026, 2:18 p.m.
Read Full Article
Vaginal Estrogen Safe for Endometrial Cancer Survivors - Mirage News

Vaginal Estrogen Safe for Endometrial Cancer Survivors Mirage News

Published: March 4, 2026, 5:04 a.m.
Read Full Article
Howard Stern, Robin Quivers, Endometrial Cancer - SurvivorNet

Howard Stern, Robin Quivers, Endometrial Cancer SurvivorNet

Published: March 4, 2026, 2:56 a.m.
Read Full Article
Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening - Nature

Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening Nature

Published: March 3, 2026, 10:36 a.m.
Read Full Article
6 Tips for Going Through Endometrial Cancer Treatment - Cleveland Clinic Health Essentials

6 Tips for Going Through Endometrial Cancer Treatment Cleveland Clinic Health Essentials

Published: March 3, 2026, 8:30 a.m.
Read Full Article
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Defense World

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Defense World

Published: March 2, 2026, 6:50 p.m.
Read Full Article
GLP-1–Progestin and Endometrial Cancer Risk - Conexiant

GLP-1–Progestin and Endometrial Cancer Risk Conexiant

Published: March 2, 2026, 5:01 p.m.
Read Full Article
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks

ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon TipRanks

Published: Feb. 27, 2026, 7:47 p.m.
Read Full Article
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat

Published: Feb. 27, 2026, 4:50 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!